BRCA2 and neoplasm: However, four metastatic breast cancer samples (hepatic metastasis and supraclavicular, pleural, hilar, and lymph nodes) infiltrated by the primary breast IDC tumor, and two patient-derived tumor xenograft (PDX) models (derived from supraclavicular and hilar metastases) showed loss of heterozygosity (LOH) in BRCA2 (Table 1, Fig. 3E–F and Figure S1B–E).